Industry Intelligence
Healthcare industry coverage focused on pharmaceutical manufacturing, proprietary brands, subscription commerce, contract distribution, medical innovation and global expansion.
Cosmos Health said preliminary nine-month 2026 revenue reached approximately $54.3 million and reaffirmed its expectation that full-year revenue will surpass $90 million, while U.S. subscriptions continued to expand.
NanoViricides said its NV-387 Oral Gummies formulation was well tolerated in a juvenile mouse study, supporting plans to consider pediatric cohorts in future clinical trials subject to further results.
DataMeds AI received Nasdaq confirmation that it had met the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). The company said it may still be subject to delisting if its next periodic report does not evidence compliance.
Cosmos Health has outlined its fourth-quarter U.S. outlook, including expected revenue of approximately $15 million and gross profit of approximately $10.5 million, while active subscriptions reached 8,940.
DataMeds AI said its Corexa Health subsidiary is preparing for potential compounded peptide activity while the FDA considers an interim access policy.
Vogenx has begun a Phase 2b trial testing two doses of mizagliflozin against placebo in adults with recurrent hypoglycemia following bariatric surgery.
Lexaria Bioscience reported results from animal study GLP-1-A26-1, which evaluated DehydraTECH-CBD and DehydraTECH-semaglutide formulations and included a reported 566% improvement in mean brain absorption for one DHT-CBD formulation.
Modular Medical has launched two digital education resources with Relevate Health Games to help prospective users learn about the Pivot tubeless patch pump before formal onboarding.
The study at Tel Aviv Sourasky University Medical Center will evaluate systemic recombinant human DNase alongside anti-CD19 CAR T-cell therapy in 12 patients with large B-cell lymphoma.